These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 32339007)

  • 1. Discontinuation of antiviral drugs may be the reason for recovered COVID-19 patients testing positive again.
    Wu F; Zhang W; Zhang L; Wang D; Wan Y
    Br J Hosp Med (Lond); 2020 Apr; 81(4):1-2. PubMed ID: 32339007
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol.
    Zeng YM; Xu XL; He XQ; Tang SQ; Li Y; Huang YQ; Harypursat V; Chen YK
    Chin Med J (Engl); 2020 May; 133(9):1132-1134. PubMed ID: 32149772
    [No Abstract]   [Full Text] [Related]  

  • 3. SARS-CoV-2 and hepatitis.
    Trevenzoli M; Guarnaccia A; Alberici I; Fassan M; Di Meco E; Farinati F; Cattelan AM
    J Gastrointestin Liver Dis; 2020 Sep; 29(3):473-475. PubMed ID: 32919428
    [No Abstract]   [Full Text] [Related]  

  • 4. BET 1: Lopinavir-ritonavir and COVID-19.
    Dolan D; Ingham J; Baombe J
    Emerg Med J; 2020 Jul; 37(7):450-451. PubMed ID: 32616658
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presumed COVID-19 index case on diamond princess cruise ship and evacuees to Hong Kong.
    Leung WS; Chan JMC; Chik TSH; Lau DPL; Choi CYC; Lau AWT; Tsang OTY
    J Travel Med; 2020 Aug; 27(5):. PubMed ID: 32396628
    [No Abstract]   [Full Text] [Related]  

  • 8. Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice.
    Levy C; Lassailly G; Parmentier E; Duburcq T; Mathurin P; Poissy J
    Am J Gastroenterol; 2020 Oct; 115(10):1716-1718. PubMed ID: 32858566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2-infected patient.
    Stalder G; Alberio L
    Blood; 2020 Aug; 136(7):915. PubMed ID: 32790855
    [No Abstract]   [Full Text] [Related]  

  • 11. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases.
    Tadolini M; Codecasa LR; García-García JM; Blanc FX; Borisov S; Alffenaar JW; Andréjak C; Bachez P; Bart PA; Belilovski E; Cardoso-Landivar J; Centis R; D'Ambrosio L; Luiza De Souza-Galvão M; Dominguez-Castellano A; Dourmane S; Fréchet Jachym M; Froissart A; Giacomet V; Goletti D; Grard S; Gualano G; Izadifar A; Le Du D; Marín Royo M; Mazza-Stalder J; Motta I; Ong CWM; Palmieri F; Rivière F; Rodrigo T; Silva DR; Sánchez-Montalvá A; Saporiti M; Scarpellini P; Schlemmer F; Spanevello A; Sumarokova E; Tabernero E; Tambyah PA; Tiberi S; Torre A; Visca D; Zabaleta Murguiondo M; Sotgiu G; Migliori GB
    Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32457198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.
    Oldenburg CE; Doan T
    Am J Trop Med Hyg; 2020 Jun; 102(6):1154-1155. PubMed ID: 32297590
    [No Abstract]   [Full Text] [Related]  

  • 13. Infection of severe acute respiratory syndrome coronavirus 2 in a patient with AIDS.
    Su J; Shen X; Ni Q; Zhao H; Cai J; Zhu B; Wu W; Lang G; Xu K; Sheng J
    AIDS; 2020 Aug; 34(10):1575-1576. PubMed ID: 32675569
    [No Abstract]   [Full Text] [Related]  

  • 14. COVID-19 pandemic and biological therapy in rheumatologic disorders: how to deal with?
    Ahmadinejad Z; Assari R; Ayoobi Yazdi N; Mazloomi SH; Javanshayani P; Khalili Afousi H; Ziaee V
    Reumatismo; 2020 Nov; 72(3):173-177. PubMed ID: 33213130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b.
    Hong SI; Ryu BH; Chong YP; Lee S; Kim S; Kim HC; Hong KW; Bae IG; Cho OH
    Int J Antimicrob Agents; 2020 Aug; 56(2):106052. PubMed ID: 32544570
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
    He F; Luo Q; Lei M; Fan L; Shao X; Hu K; Qin S; Yu N; Cao J; Yang L
    Clin Rheumatol; 2020 Sep; 39(9):2803-2810. PubMed ID: 32725351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia.
    Beyls C; Martin N; Hermida A; Abou-Arab O; Mahjoub Y
    Circ Arrhythm Electrophysiol; 2020 Aug; 13(8):e008798. PubMed ID: 32809882
    [No Abstract]   [Full Text] [Related]  

  • 18. [Differential diagnosis of pneumonia at the time of COVID-19].
    Fragiel M; Canora Lebrato J; Candel FJ; Zapatero Gaviria A; Marco Martínez J; González Del Castillo J
    Rev Esp Quimioter; 2020 Oct; 33(5):387-389. PubMed ID: 32741193
    [No Abstract]   [Full Text] [Related]  

  • 19. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
    Cao B; Wang Y; Wen D; Liu W; Wang J; Fan G; Ruan L; Song B; Cai Y; Wei M; Li X; Xia J; Chen N; Xiang J; Yu T; Bai T; Xie X; Zhang L; Li C; Yuan Y; Chen H; Li H; Huang H; Tu S; Gong F; Liu Y; Wei Y; Dong C; Zhou F; Gu X; Xu J; Liu Z; Zhang Y; Li H; Shang L; Wang K; Li K; Zhou X; Dong X; Qu Z; Lu S; Hu X; Ruan S; Luo S; Wu J; Peng L; Cheng F; Pan L; Zou J; Jia C; Wang J; Liu X; Wang S; Wu X; Ge Q; He J; Zhan H; Qiu F; Guo L; Huang C; Jaki T; Hayden FG; Horby PW; Zhang D; Wang C
    N Engl J Med; 2020 May; 382(19):1787-1799. PubMed ID: 32187464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
    Barlow A; Landolf KM; Barlow B; Yeung SYA; Heavner JJ; Claassen CW; Heavner MS
    Pharmacotherapy; 2020 May; 40(5):416-437. PubMed ID: 32259313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.